Compared to Estimates, Constellation Brands (STZ) Q4 Earnings: A Look at Key Metrics

Constellation Brands (STZ Quick QuoteSTZ – Free Report) reported $2.16 billion in revenue for the quarter ended February 2025, representing a year-over-year increase of 1.2%. EPS of $2.63 for the same period compares to $2.26 a year ago.

The reported revenue represents a surprise of +1.53% over the Zacks Consensus Estimate of $2.13 billion. With the consensus EPS estimate being $2.28, the EPS surprise was +15.35%.

While investors closely watch year-over-year changes in headline numbers — revenue and earnings — and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company’s underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock’s price performance more accurately.

Here is how Constellation Brands performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Wine and Spirits: $459.80 million versus $406.65 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.4% change.
• Net Sales- Beer: $1.70 billion versus the five-analyst average estimate of $1.72 billion. The reported number represents a year-over-year change of +0.1%.
• Operating Income- Wine and Spirits: $99.70 million versus $89.71 million estimated by four analysts on average.
• Operating Income- Beer: $623.80 million compared to the $604.10 million average estimate based on four analysts.
• Operating Income- Corporate Operations and Other: -$64.60 million versus -$66.41 million estimated by three analysts on average.

View all Key Company Metrics for Constellation Brands here>>>

Shares of Constellation Brands have returned -7.7% over the past month versus the Zacks S&P 500 composite’s -13.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.